Company intelligence / Profile preview

Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd.

Ownership: Private
Employees: ~5412
Development stage: Commercial

Overview

Mandi Foam completed Phase III study showing equivalent efficacy and similar safety and tolerability as ROGAINE®. Mandi (5% minoxidil) Foam was approved for market launch in January 2024 as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata. Mandi has achieved a compound annual growth rate of 77% for four consecutive years.

Therapeutic areas: PulmonologyDermatologyEndocrinology
Modalities: Small moleculesbiologics
Industry: Biotech

Drug pipeline

2 assets

Yilixi

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Hybio Pharmaceutical (for Semaglutide WM)

Beyond the preview

Go deeper on Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd..

Explore the full profile